GAMMA Investing LLC Increases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

GAMMA Investing LLC increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 24,226.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 210,427 shares of the medical research company's stock after acquiring an additional 209,562 shares during the quarter. GAMMA Investing LLC owned approximately 0.41% of Charles River Laboratories International worth $31,673,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of CRL. D1 Capital Partners L.P. purchased a new position in Charles River Laboratories International during the 4th quarter worth $172,752,000. Norges Bank acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $98,886,000. Wellington Management Group LLP grew its holdings in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after buying an additional 335,658 shares during the last quarter. Nomura Holdings Inc. acquired a new position in Charles River Laboratories International in the 4th quarter valued at about $56,820,000. Finally, Raymond James Financial Inc. purchased a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $42,776,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Mizuho decreased their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Robert W. Baird increased their price target on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $188.00 to $182.00 in a research report on Friday, May 23rd. Barclays boosted their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $171.85.

Charles River Laboratories International Price Performance

Shares of CRL traded up $3.53 during trading hours on Friday, reaching $144.73. The company had a trading volume of 937,845 shares, compared to its average volume of 997,956. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The firm has a 50 day simple moving average of $127.72 and a 200-day simple moving average of $158.50. The company has a market capitalization of $7.11 billion, a price-to-earnings ratio of 964.87, a PEG ratio of 4.54 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same period last year, the company posted $2.27 earnings per share. The firm's quarterly revenue was down 2.7% compared to the same quarter last year. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).